MedPath

Comparison of Efonidipine/Irbesartan combination and Irbesartan monotherapy for uncontrolled hypertensio

Phase 4
Conditions
Hypertension
Registration Number
JPRN-UMIN000002242
Lead Sponsor
Kyoto University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. pregnant patients 2. patients with severe liver dysfunction 3. patients with severe renal dysfunction 4. allergic to irbesartan or efonidipine 5. patients judged to be inappropriate for this study by attending physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
blood pressure lowering after 1 month
Secondary Outcome Measures
NameTimeMethod
1. blood pressure lowering after 6 months 2. Change in albuminuria after 6 months 3. adverse events
© Copyright 2025. All Rights Reserved by MedPath